EpiBone

EpiBone is a New York-based tissue engineering company founded in 2013, developing autologous and allogenic bone and cartilage grafts. Its core technology involves extracting a patient's stem cells, seeding them onto a scaffold within a custom bioreactor that mimics the body's natural environment, and growing a personalized, living graft in 3-4 weeks. The company has advanced its lead bone graft program through a Phase I/IIa trial and has an FDA-cleared IND for a Phase I/IIb trial of its osteochondral plug, positioning it at the forefront of regenerative orthopedics. EpiBone aims to address the significant global burden of skeletal disability with biologically integrated, long-lasting solutions.

Proprietary bioreactor platform that uses patient-specific or donor stem cells, seeded onto a 3D scaffold, to grow living, anatomically precise bone and cartilage grafts under controlled mechanical and biochemical conditions.

EpiBone competes in the regenerative orthopedics space against companies developing synthetic bone substitutes (e.g., Medtronic, Stryker), traditional allograft processors, and other cell therapy approaches. Direct competitors include other tissue engineering firms working on bone/cartilage (e.g., Histogenics in the past, various startups). EpiBone's key differentiator is its focus on growing anatomically precise, living grafts using a proprietary bioreactor system that applies mechanical stimulation.